Chapter 8
A tissue-engineered construct is certified one batch at a time. A scaffold that is 75% porous on the drawing may come out of the printer with closed pores. A bioink that was 95% viable in the cartridge may reach the dish at 70% after shear in the nozzle. A culture that ran correctly for three weeks still counts for nothing if the sterility record is missing. WIA-BIO-006 is therefore best read as a chain of checkpoints: design parameters, fabrication parameters, culture parameters, and release tests. Each checkpoint has a numeric acceptance threshold and a record that proves it was met. This chapter follows that chain from the software components a compliant system needs to the regulatory path a finished construct travels.
Section 9.1 of the specification names five components that any compliant system must include. Each one corresponds to a point in the construct's life where a decision is made and must be documented:
The list matters because it separates the data a project produces from the people who produce it. A university group may run all five as a single spreadsheet and a lab notebook. A GMP manufacturer will spread them across several validated systems. Either way the standard asks the same question: for a given construct, can you show the designed scaffold, the print record, the culture trace, the test results and the batch documentation, and do they agree with one another?
The shared language between those components is a small set of formulas, one configuration record and two request/response contracts. Defining them in one place lets design software, printer firmware and bioreactor controllers exchange numbers without re-interpreting them.
Version 1.0 describes a scaffold in a single JSON configuration. It groups the material (type, blend ratio, cross-linking agent), the architecture (porosity, pore size, interconnectivity), the dimensions and the mechanical properties:
{
"scaffold_id": "SCF-2025-001",
"material": { "type": "pcl-collagen", "ratio": "70:30", "crosslinking": "EDC" },
"architecture": { "porosity": 75, "pore_size": 200, "interconnectivity": 95 },
"dimensions": { "length": 10, "width": 10, "height": 3, "unit": "mm" },
"mechanical": { "youngs_modulus": 50, "ultimate_strength": 5, "unit": "MPa" }
}Each architecture field links to a formula in the specification, so the number in the record can be audited rather than merely declared:
P = (1 - rho_apparent / rho_material) x 100% porosity
d_pore = 6 x V_void / S_pore average pore diameter
I = (N_connected / N_total) x 100% interconnectivity (minimum 90%)
E = sigma / epsilon, sigma = F / A0 compression modulus
F = (1 - |D_actual - D_design| / D_design) x 100% print fidelity (target above 90%)The example record is a 70:30 PCL-collagen composite. The specification gives this blend a modulus of 50–150 MPa and a porosity of 65–80%, and the record's 75% porosity and 50 MPa both sit inside those ranges. The record also shows an engineering trade-off. The native-bone entry in the specification's tissue table is 10–20 GPa, so a porous composite of this kind is orders of magnitude softer. A bone scaffold is therefore never validated on porosity alone. The mechanical section of the record has to be compared with the target tissue.
Two TypeScript interfaces in section 9.2 define the operations that act on such records:
interface ScaffoldRequest {
tissueType: string;
material: BiomaterialType;
porosity: number; // percentage
poreSize: number; // micrometers
dimensions: { length: number; width: number; height: number }; // mm
}
interface ScaffoldResponse {
id: string;
volume: number; // mm³
surfaceArea: number; // mm²
cellCapacity: number; // cells
mechanicalProperties: MechanicalProperties;
fabricationMethod: string;
}
interface CultureRequest {
tissueConstruct: TissueConstruct;
cellType: string;
duration: number; // days
bioreactorType: string;
}
interface CultureResponse {
flowRate: number; // mL/min
oxygenLevel: number; // percentage
temperature: number; // celsius
shearStress: number; // dyne/cm²
predictedMaturation: number; // days
qualityScore: number; // 0-1
}The two contracts divide the work in a way that matches the biology. Design Scaffold takes a tissue type, material, porosity, pore size and size in millimetres. It returns volume, surface area and a cell capacity, which is what the seeding step needs to size its cell suspension. Optimize Culture takes the construct, the cell type, the planned duration and the bioreactor type. It returns the operating point (flow rate, oxygen level, temperature, shear stress), a predicted maturation time in days and a 0–1 quality score. The shear stress field is the one to watch. The perfusion bioreactor section gives 0.1–10 dyne/cm² as the typical range, and a controller that lets this drift can damage a construct without any visible alarm.
The only error code the material spells out is B001, "Insufficient porosity", whose recommended action is to increase pore size. It is a useful example of what a code should do: it names the physical cause and points to the design variable that fixes it. Implementers who add their own codes should keep to that pattern.
The specification does not size a market, and this chapter does not either. What the document does show is where adoption pressure lands. Scaffold and biomaterial suppliers need a common way to state porosity, modulus and degradation time. Bioprinter makers need to express resolution and cell viability in the same terms. Bioreactor vendors need to report flow and shear the same way. Manufacturers working under GMP need records that regulators can follow from a finished construct back to its raw materials. The five required components map onto these four groups, which is why a single standard can cover them without requiring every party to buy the same hardware.
Applications differ mainly in what counts as "right" for a given tissue. The standard handles this by tabulating tissue-specific targets rather than prescribing one recipe.
The table below collects values from different parts of the specification. It shows how one set of data fields yields very different configurations.
| Tissue | Recommended porosity | Young's modulus (target) | Seeding density guideline |
|---|---|---|---|
| Bone | 60–80% | 10–20 GPa | 5 × 10⁶ – 2 × 10⁷ cells/cm³ |
| Cartilage | 70–85% | 0.5–2 MPa | 2 × 10⁷ – 6 × 10⁷ cells/cm³ |
| Skin | 80–95% | 0.1–2 MPa | 1 × 10⁶ – 5 × 10⁶ cells/cm² |
| Liver | 85–90% | 0.5–1 kPa | 5 × 10⁷ – 2 × 10⁸ cells/cm³ |
| Cardiac | not specified | 10–50 kPa | not specified |
Pore size follows the cell type. The specification lists 100–400 μm for osteoblasts, 50–150 μm for fibroblasts, 30–100 μm for endothelial cells and 20–50 μm for hepatocytes. A liver construct therefore needs a dense, soft, finely porous structure. A bone construct needs a stiff, coarsely porous one. The same Scaffold Designer produces both, but its acceptance windows differ.
The fabrication route is chosen against the same targets. Extrusion bioprinting (10–200 kPa, 100–1000 μm nozzles) tolerates high cell density of 10⁶–10⁸ cells/mL but has lower resolution and exposes cells to shear. Inkjet printing reaches 20–100 μm resolution with viability above 85%, but it needs low-viscosity inks of 3–12 mPa·s. Laser-assisted printing (LIFT) gives below 10 μm resolution and viability above 95%, but it is costly and slow. A thick, cell-dense cartilage plug and a thin, finely patterned endothelial layer would reasonably be built by different routes, and the record should say which route was used, as the fabricationMethod field in ScaffoldResponse does.
The testing and regulatory sections define what a certifiable construct must demonstrate. The Quality Validator component is meant to run these tests and attach their results to the batch record.
Release testing falls into five groups, each with its own acceptance line:
These tests set the evidence required for the regulatory route. The specification describes most tissue-engineered products as FDA Class II (510(k) notification, GMP, Quality System Regulation) and high-risk products as Class III (premarket approval with Phase I–III clinical trials). GMP expectations are validated processes, a controlled environment (ISO 5–7 cleanroom), documented SOPs, batch-level traceability and in-process testing. Preclinical work proceeds in order: in vitro biocompatibility under ISO 10993, small animals (rat, rabbit), large animals (pig, sheep), dose-response studies and long-term safety over 6–12 months. Clinical phases follow, from safety in 10–30 patients through efficacy in 30–100 to confirmatory trials in 100–1000. The Phase 4 integration notes also place FDA HCT/P rules and the European ATMP framework in the surrounding ecosystem. Which route applies depends on the product, and a team should settle it before the first batch record is written.
The platform layer around these tests is deliberately conventional. It consists of role-based access, encrypted storage and transport, and audit logging. It exists so that the batch record can be trusted, and it does not change the science. The domain content is the numeric acceptance lines above.
Most failures in practice happen between the design record and the first culture. Four points deserve attention.
cellCapacity value is only the ceiling. The seeded number depends on the method, so the record should log the method together with the suspension density.The v1.0 contracts cover two operations, scaffold design and culture optimisation. The bioprinting module, quality validator and documentation system are named as required components but are not given request/response shapes of their own. Extending the interface surface to print telemetry, bioreactor telemetry and release-test results is the most obvious next step for implementers, and it should reuse the existing records and units. The standard's own vascularisation and perfusion material points in the same direction. Larger constructs depend on perfusion, and perfusion data (flow, pressure, shear) will need the same disciplined recording as the scaffold configuration.
Certification under WIA-BIO-006 comes from consistency across five stages: scaffold design, bioprinting, culture, quality validation and documentation. The scaffold configuration record, with its porosity, pore size, interconnectivity and mechanical fields, carries design intent. The ScaffoldRequest/ScaffoldResponse and CultureRequest/CultureResponse contracts connect design to culture. Fixed acceptance lines (interconnectivity of at least 90%, print fidelity above 90%, post-print viability of at least 80%, endotoxin below 0.5 EU/mL, cytotoxicity viability above 70%, an in vivo score of 1 or lower) turn those records into release decisions. The regulatory path adds GMP controls, preclinical sequencing and, for higher-risk products, phased clinical trials. The practical advice from this chapter is to check seeding efficiency, print fidelity and shear exposure by measurement, because these are the points where a design that looks sound on paper fails in the lab.
The next chapter picks up from here. Where this chapter looked at building and qualifying a compliant system, the next turns to how such systems are used and extended once they are running.